Gabor G. Illei

Best Publications

• Anifrolumab, an Anti–Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus

  Richard Furie;Munther Khamashta;Joan T. Merrill;Victoria P. Werth

  970
  Citations

• Deficient CD4+CD25high T Regulatory Cell Function in Patients with Active Systemic Lupus Erythematosus

  Xavier Valencia;Cheryl Yarboro;Gabor Illei;Peter E. Lipsky

  870
  Citations

• Identification and characterization of circulating human transitional B cells

  Gary P. Sims;Rachel Ettinger;Yuko Shirota;Cheryl H. Yarboro

  816
  Citations

• A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis.

  Dimitrios T. Boumpas;Richard Furie;Susan Manzi;Gabor G. Illei

  704
  Citations

• Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study

  Gabor G. Illei;Yuko Shirota;Cheryl H. Yarboro;Jimmy Daruwalla

  697
  Citations

• Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study

  Munther Khamashta;Joan T Merrill;Victoria P Werth;Victoria P Werth;Richard Furie

  521
  Citations

• BASOPHILS AND THE T HELPER 2 ENVIRONMENT CAN PROMOTE THE DEVELOPMENT OF LUPUS NEPHRITIS

  Nicolas Charles;Donna Hardwick;Eric Daugas;Gabor G Illei

  443
  Citations

• Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies.

  G. G. Illei;K. Takada;D. Parkin;H. A. Austin

  424
  Citations

• Rationale for interleukin-6 blockade in systemic lupus erythematosus

  E Tackey;P E Lipsky;G G Illei

  413
  Citations

• Randomized, Controlled Trial of Prednisone, Cyclophosphamide, and Cyclosporine in Lupus Membranous Nephropathy

  Howard A. Austin;Gabor G. Illei;Michelle J. Braun;James E. Balow

  358
  Citations

• Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions

  Amrie C. Grammer;Rebecca Slota;Randy Fischer;Hanan Gur

  354
  Citations

• Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus.

  Larissa Lapteva;Miroslawa Nowak;Cheryl H. Yarboro;Kazuki Takada

  305
  Citations

• MicroRNAs as biomarkers in rheumatic diseases

  Unknown

  280
  Citations

• Selective expression of latency-associated peptide (LAP) and IL-1 receptor type I/II (CD121a/CD121b) on activated human FOXP3+ regulatory T cells allows for their purification from expansion cultures

  Dat Q. Tran;John Andersson;Donna Hardwick;Lolita Bebris

  265
  Citations

• Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions

  Unknown

  221
  Citations

• Early responses to adenoviral-mediated transfer of the aquaporin-1 cDNA for radiation-induced salivary hypofunction.

  Bruce J. Baum;Ilias Alevizos;Changyu Zheng;Ana P. Cotrim

  216
  Citations

• Variant form of STAT4 is associated with primary Sjögren's syndrome

  B D Korman;M I Alba;J M Le;I Alevizos

  203
  Citations

• MicroRNA Expression Profiles as Biomarkers of Minor Salivary Gland Inflammation and Dysfunction in Sjögren's Syndrome

  Ilias Alevizos;Stefanie Alexander;R. James Turner;Gabor G. Illei

  203
  Citations

• Pathogenesis of Sjögren's syndrome

  Nikolay P Nikolov;Gabor G Illei

  200
  Citations

• Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis.

  Kazuki Takada;Million Arefayene;Zeruesenay Desta;Cheryl H. Yarboro

  200
  Citations